Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,095 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: B cell infusion Clear all

Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
Interventions: LN-145, Cyclophosphamide, Fludarabine, Interleukin-2; Biological · Drug
Lead sponsor: Karam Khaddour, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Glioma, High Grade Glioma
Interventions: TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine; Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 3 Years to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida

Conditions: Hematologic Diseases
Interventions: Allogeneic Stem Cell Transplant, CliniMACS TCR α/β Reagent Kit and CliniMACS CD19; Biological · Device
Lead sponsor: Alice Bertaina; Other
Eligibility: 1 Month to 60 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Interventions: brentuximab vedotin, rituximab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more

Conditions: Leukemia, Lymphoma, Myelodysplasia
Interventions: CliniMACS α/β T-Cell and CD19+ B-Cell Depleted Peripheral Blood Stem Cell Transplant; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 23 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma, T Cell Lymphomas, Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia
Interventions: cellular immunotherapy; Biological
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Non-Hodgkin's Lymphoma
Interventions: Rituxan, 1018 ISS; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: JNJ-68284528; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 11 more

Conditions: Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma, Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions: CLBR001 and SWI019; Combination Product
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Duarte, California • San Diego, California • Chicago, Illinois + 5 more

Conditions: COVID-19
Interventions: BRII-196, BRII-198, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 76
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Drug · Other · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 3
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Interventions: Fludarabine, Cyclophosphamide, CD19-CD34 CAR transduced T cells; Drug · Biological
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Chronic Obstructive Pulmonary Disease, Emphysema
Interventions: Belimumab, Placebo; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Myeloma
Interventions: PHE885; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Stichting European Myeloma Network; Network
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 27
States / cities: Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more

Conditions: Leukemia, Lymphoma, Lymphoma, B-Cell
Interventions: CAR T-Cell Infusion; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Waldenström Macroglobulinemia
Interventions: alvocidib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
Interventions: OR502, Cemiplimab; Drug
Lead sponsor: OncoResponse, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more

Conditions: High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: ALT-803; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma, Myelodysplastic Syndrome
Interventions: Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS; Procedure · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Non Small Cell Lung Carcinoma, c-MET
Interventions: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions: Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol; Drug · Biological · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: B-Cell Chronic Lymphocytic Leukemia
Interventions: FluCAM [Fludara + Campath], fludarabine phosphate; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Fort Myers, Florida

Search by objective public record fields.

TIL Therapy in cSCC and MCC

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients